College of Pharmacy Faculty Research and Publications
New Drugs: Faricimab-svoa (Vabysmo™) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti™) for Glaucoma and Ocular Hypertension
Document Type
Article
Publication Title
The Senior Care Pharmacist
Publication Date
12-1-2023
Volume
38
Issue
12
First Page
497
Last Page
500
Abstract
Two drugs are covered in this quarterly column. Faricimab-svoa (Vabysmo™) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti™) for Glaucoma and Ocular Hypertension.
Copyright held by
American Society of Consultant Pharmacists
Recommended Citation
Gettman, L. (2023). New Drugs: Faricimab-svoa (Vabysmo™) for Macular Degeneration and Diabetic Macular Edema and Omidenepag Isopropyl (Omlonti™) for Glaucoma and Ocular Hypertension. The Senior Care Pharmacist, 38 (12), 497-500. http://dx.doi.org/https://doi.org/10.4140/TCP.n.2023.497
COinS
